Natural Health Science News The latest news and top resources on natural health.

ADHD/ADD Treatment – Update July 2018

Posted October 2, 2018

Comparison of the effect of pharmacotherapy and neuro-feedback therapy on oral health of children with attention deficit hyperactivity disorder.

Vafaei, A., I. Vafaei, G. Noorazar, R. Akbarzadeh, L. Erfanparast, and S. Shirazi. “Comparison of the Effect of Pharmacotherapy and Neuro-Feedback Therapy on Oral Health of Children with Attention Deficit Hyperactivity Disorder.” [In eng]. J Clin Exp Dent 10, no. 4 (Apr 2018): e306-e11.

Expectancy Effects on Self-Reported Attention-Deficit/Hyperactivity Disorder Symptoms in Simulated Neurofeedback: A Pilot Study.

Lee, G. J., and J. A. Suhr. “Expectancy Effects on Self-Reported Attention-Deficit/Hyperactivity Disorder Symptoms in Simulated Neurofeedback: A Pilot Study.” [In eng]. Arch Clin Neuropsychol (Mar 31 2018).

fMRI Neurofeedback Training for Increasing Anterior Cingulate Cortex Activation in Adult Attention Deficit Hyperactivity Disorder. An Exploratory Randomized, Single-Blinded Study.

Zilverstand, A., B. Sorger, D. Slaats-Willemse, C. C. Kan, R. Goebel, and J. K. Buitelaar. “Fmri Neurofeedback Training for Increasing Anterior Cingulate Cortex Activation in Adult Attention Deficit Hyperactivity Disorder. An Exploratory Randomized, Single-Blinded Study.” [In eng]. PLoS One 12, no. 1 (2017): e0170795.

A Randomized Trial of Comparing the Efficacy of Two Neurofeedback Protocols for Treatment of Clinical and Cognitive Symptoms of ADHD: Theta Suppression/Beta Enhancement and Theta Suppression/Alpha Enhancement.

Mohagheghi, A., S. Amiri, N. Moghaddasi Bonab, G. Chalabianloo, S. G. Noorazar, S. M. Tabatabaei, and S. Farhang. “A Randomized Trial of Comparing the Efficacy of Two Neurofeedback Protocols for Treatment of Clinical and Cognitive Symptoms of Adhd: Theta Suppression/Beta Enhancement and Theta Suppression/Alpha Enhancement.” [In eng]. Biomed Res Int 2017 (2017): 3513281.

Dietary factors in the etiology and therapy of attention deficit/hyperactivity disorder.

Lange, K. W. “Dietary Factors in the Etiology and Therapy of Attention Deficit/Hyperactivity Disorder.” [In eng]. Curr Opin Clin Nutr Metab Care 20, no. 6 (Nov 2017): 464-69.

Cognitive Neuroscience of Attention Deficit Hyperactivity Disorder (ADHD) and Its Clinical Translation.

Rubia, K. “Cognitive Neuroscience of Attention Deficit Hyperactivity Disorder (Adhd) and Its Clinical Translation.” [In eng]. Front Hum Neurosci 12 (2018): 100.

Mind-Body Therapy for Children with Attention-Deficit/Hyperactivity Disorder.

Herbert, A., and A. Esparham. “Mind-Body Therapy for Children with Attention-Deficit/Hyperactivity Disorder.” [In eng]. Children (Basel) 4, no. 5 (Apr 25 2017).

The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials.

Catala-Lopez, F., B. Hutton, A. Nunez-Beltran, M. J. Page, M. Ridao, D. Macias Saint-Gerons, M. A. Catala, R. Tabares-Seisdedos, and D. Moher. “The Pharmacological and Non-Pharmacological Treatment of Attention Deficit Hyperactivity Disorder in Children and Adolescents: A Systematic Review with Network Meta-Analyses of Randomised Trials.” [In eng]. PLoS One 12, no. 7 (2017): e0180355.

Systematic review of meditation-based interventions for children with ADHD.

Evans, S., M. Ling, B. Hill, N. Rinehart, D. Austin, and E. Sciberras. “Systematic Review of Meditation-Based Interventions for Children with Adhd.” [In eng]. Eur Child Adolesc Psychiatry 27, no. 1 (Jan 2018): 9-27.

Nonpharmacologic Treatments for Attention-Deficit/Hyperactivity Disorder: A Systematic Review.

Goode, A. P., R. R. Coeytaux, G. R. Maslow, N. Davis, S. Hill, B. Namdari, N. M. A. LaPointe, et al. “Nonpharmacologic Treatments for Attention-Deficit/Hyperactivity Disorder: A Systematic Review.” [In eng]. Pediatrics 141, no. 6 (Jun 2018).

Neurofeedback Training for Psychiatric Disorders Associated with Criminal Offending: A Review.

Fielenbach, S., F. C. L. Donkers, M. Spreen, H. A. Visser, and S. Bogaerts. “Neurofeedback Training for Psychiatric Disorders Associated with Criminal Offending: A Review.” [In eng]. Front Psychiatry 8 (2017): 313.

Effect of vitamin D supplementation as adjunctive therapy to methylphenidate on ADHD symptoms: A randomized, double blind, placebo-controlled trial.

Fielenbach, S., F. C. L. Donkers, M. Spreen, H. A. Visser, and S. Bogaerts. “Neurofeedback Training for Psychiatric Disorders Associated with Criminal Offending: A Review.” [In eng]. Front Psychiatry 8 (2017): 313.

Trend, characteristics, and pharmacotherapy of adults diagnosed with attention-deficit/hyperactivity disorder: a nationwide survey in Taiwan.

Cheng, Y. S., Y. C. Shyu, S. Y. Lee, S. S. Yuan, C. J. Yang, K. C. Yang, T. L. Lee, and L. J. Wang. “Trend, Characteristics, and Pharmacotherapy of Adults Diagnosed with Attention-Deficit/Hyperactivity Disorder: A Nationwide Survey in Taiwan.” [In eng]. Neuropsychiatr Dis Treat 13 (2017): 643-51.

Effect of Pycnogenol on attention-deficit hyperactivity disorder (ADHD): study protocol for a randomised controlled trial.

Verlaet, A. A., B. Ceulemans, H. Verhelst, D. Van West, T. De Bruyne, L. Pieters, H. F. Savelkoul, and N. Hermans. “Effect of Pycnogenol(R) on Attention-Deficit Hyperactivity Disorder (Adhd): Study Protocol for a Randomised Controlled Trial.” [In eng]. Trials 18, no. 1 (Mar 28 2017): 145.

Are psychiatric comorbidities and associated cognitive functions related to treatment response to methylphenidate in boys with attention-deficit/hyperactivity disorder?

Chan, M. H., P. W. Leung, T. P. Ho, S. F. Hung, C. C. Lee, C. P. Tang, K. C. Cheung, et al. “Are Psychiatric Comorbidities and Associated Cognitive Functions Related to Treatment Response to Methylphenidate in Boys with Attention-Deficit/Hyperactivity Disorder?” [In eng]. Neuropsychiatr Dis Treat 13 (2017): 1071-80.

Chiral Analysis of Amphetamines in Hair by Liquid Chromatography-Tandem Mass Spectrometry: Compliance-Monitoring of attention deficit hyperactivity disorder (ADHD) patients under Elvanse therapy and identification after controlled low dose application.

Binz, T. M., E. Williner, P. Strajhar, P. C. Dolder, M. E. Liechti, M. R. Baumgartner, T. Kraemer, and A. E. Steuer. “Chiral Analysis of Amphetamines in Hair by Liquid Chromatography-Tandem Mass Spectrometry: Compliance-Monitoring of Attention Deficit Hyperactivity Disorder (Adhd) Patients under Elvanse(R) Therapy and Identification after Controlled Low-Dose Application.” [In eng]. Drug Test Anal 10, no. 2 (Feb 2018): 254-61.

A 6-month follow-up of an RCT on behavioral and neurocognitive effects of neurofeedback in children with ADHD.

Gelade, K., T. W. P. Janssen, M. Bink, J. W. R. Twisk, R. van Mourik, A. Maras, and J. Oosterlaan. “A 6-Month Follow-up of an Rct on Behavioral and Neurocognitive Effects of Neurofeedback in Children with Adhd.” [In eng]. Eur Child Adolesc Psychiatry 27, no. 5 (May 2018): 581-93.

Co-occurring Attention Deficit Hyperactivity Disorder symptoms in adults affected by heroin dependence: Patients characteristics and treatment needs.

Lugoboni, F., F. R. Levin, M. C. Pieri, M. Manfredini, L. Zamboni, L. Somaini, G. Gerra, and Gics Gruppo InterSert Collaborazione Scientifica. “Co-Occurring Attention Deficit Hyperactivity Disorder Symptoms in Adults Affected by Heroin Dependence: Patients Characteristics and Treatment Needs.” [In eng]. Psychiatry Res 250 (Apr 2017): 210-16.

Screening for adult attention deficit/hyperactivity disorder in high-dose benzodiazepine dependent patients.

Tamburin, S., A. Federico, L. Morbioli, M. Faccini, R. Casari, L. Zamboni, G. Briguglio, and F. Lugoboni. “Screening for Adult Attention Deficit/Hyperactivity Disorder in High-Dose Benzodiazepine Dependent Patients.” [In eng]. Am J Addict 26, no. 6 (Sep 2017): 610-14.

Components of Motor Deficiencies in ADHD and Possible Interventions.

Dahan, A., C. H. Ryder, and M. Reiner. “Components of Motor Deficiencies in Adhd and Possible Interventions.” [In eng]. Neuroscience 378 (May 15 2018): 34-53.

Neurofeedback of Slow Cortical Potentials in Children with Attention-Deficit/Hyperactivity Disorder: A Multicenter Randomized Trial Controlling for Unspecific Effects.

Strehl, U., P. Aggensteiner, D. Wachtlin, D. Brandeis, B. Albrecht, M. Arana, C. Bach, et al. “Neurofeedback of Slow Cortical Potentials in Children with Attention-Deficit/Hyperactivity Disorder: A Multicenter Randomized Trial Controlling for Unspecific Effects.” [In eng]. Front Hum Neurosci 11 (2017): 135.

ESCAschool study: trial protocol of an adaptive treatment approach for school-age children with ADHD including two randomised trials.

Dopfner, M., C. Hautmann, C. Dose, T. Banaschewski, K. Becker, D. Brandeis, M. Holtmann, et al. “Escaschool Study: Trial Protocol of an Adaptive Treatment Approach for School-Age Children with Adhd Including Two Randomised Trials.” [In eng]. BMC Psychiatry 17, no. 1 (Jul 24 2017): 269.

Attention-Deficit/Hyperactivity Disorder.

Banaschewski, T., K. Becker, M. Dopfner, M. Holtmann, M. Rosler, and M. Romanos. “Attention-Deficit/Hyperactivity Disorder.” [In eng]. Dtsch Arztebl Int 114, no. 9 (Mar 3 2017): 149-59.

Driving and attention deficit hyperactivity disorder.

Fuermaier, A. B., L. Tucha, B. L. Evans, J. Koerts, D. de Waard, K. Brookhuis, S. Aschenbrenner, et al. “Driving and Attention Deficit Hyperactivity Disorder.” [In eng]. J Neural Transm (Vienna) 124, no. Suppl 1 (Feb 2017): 55-67.Fuermaier, A. B., L. Tucha, B. L. Evans, J. Koerts, D. de Waard, K. Brookhuis, S. Aschenbrenner, et al. “Driving and Attention Deficit Hyperactivity Disorder.” [In eng]. J Neural Transm (Vienna) 124, no. Suppl 1 (Feb 2017): 55-67.

Multimodal treatment in children and adolescents with attention-deficit/hyperactivity disorder: a 6-month follow-up.

Duric, N. S., J. Assmus, D. Gundersen, A. Duric Golos, and I. B. Elgen. “Multimodal Treatment in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A 6-Month Follow-Up.” [In eng]. Nord J Psychiatry 71, no. 5 (Jul 2017): 386-94.

Evaluating the features of the brain waves to quantify ADHD improvement by neurofeedback.

Dehghanpour, P., and Z. Einalou. “Evaluating the Features of the Brain Waves to Quantify Adhd Improvement by Neurofeedback.” [In eng]. Technol Health Care 25, no. 5 (Oct 23 2017): 877-85.

Auditory Processing Assessment in Children with Attention Deficit Hyperactivity Disorder: An Open Study Examining Methylphenidate Effects.

Lanzetta-Valdo, B. P., G. A. Oliveira, J. T. Ferreira, and E. M. Palacios. “Auditory Processing Assessment in Children with Attention Deficit Hyperactivity Disorder: An Open Study Examining Methylphenidate Effects.” [In eng]. Int Arch Otorhinolaryngol 21, no. 1 (Jan 2017): 72-78.

Pharmacological Treatment of Attention Deficit Hyperactivity Disorder During Pregnancy and Lactation.

Ornoy, A. “Pharmacological Treatment of Attention Deficit Hyperactivity Disorder During Pregnancy and Lactation.” [In eng]. Pharm Res 35, no. 3 (Feb 6 2018): 46.

Neurofeedback Training Effects on Inhibitory Brain Activation in ADHD: A Matter of Learning?

Baumeister, S., I. Wolf, N. Holz, R. Boecker-Schlier, N. Adamo, M. Holtmann, M. Ruf, et al. “Neurofeedback Training Effects on Inhibitory Brain Activation in Adhd: A Matter of Learning?” [In eng]. Neuroscience 378 (May 15 2018): 89-99.

Predictive factors of success in neurofeedback training for children with ADHD.

Okumura, Y., Y. Kita, M. Omori, K. Suzuki, A. Yasumura, A. Fukuda, and M. Inagaki. “Predictive Factors of Success in Neurofeedback Training for Children with Adhd.” [In eng]. Dev Neurorehabil (Jun 8 2017): 1-10.

Attention deficit hyperactivity disorder pharmacotherapy in Slovenian adults: a population-based study.

Stuhec, M., and I. Locatelli. “Attention Deficit Hyperactivity Disorder Pharmacotherapy in Slovenian Adults: A Population-Based Study.” [In eng]. Int J Clin Pharm 40, no. 2 (Apr 2018): 341-44.

A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK.

Zimovetz, E. A., A. Joseph, R. Ayyagari, and J. A. Mauskopf. “A Cost-Effectiveness Analysis of Lisdexamfetamine Dimesylate in the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder in the Uk.” [In eng]. Eur J Health Econ 19, no. 1 (Jan 2018): 21-35.

Attention-Deficit Hyperactivity Disorder: Clinical Considerations for Women.

Marraccini, M. E., L. L. Weyandt, B. G. Gudmundsdottir, D. R. Oster, and A. McCallum. “Attention-Deficit Hyperactivity Disorder: Clinical Considerations for Women.” [In eng]. J Midwifery Womens Health 62, no. 6 (Nov 2017): 684-95.

Efficacy and safety of drugs for attention deficit hyperactivity disorder in children and adolescents: a network meta-analysis.

Padilha, Scos, S. Virtuoso, F. S. Tonin, H. H. L. Borba, and R. Pontarolo. “Efficacy and Safety of Drugs for Attention Deficit Hyperactivity Disorder in Children and Adolescents: A Network Meta-Analysis.” [In eng]. Eur Child Adolesc Psychiatry (Feb 19 2018).

Pediatric pharmacoepidemiology – safety and effectiveness of medicines for ADHD.

Clavenna, A., and M. Bonati. “Pediatric Pharmacoepidemiology – Safety and Effectiveness of Medicines for Adhd.” [In eng]. Expert Opin Drug Saf 16, no. 12 (Dec 2017): 1335-45.

Lost in transition: A review of the unmet need of patients with attention deficit/hyperactivity disorder transitioning to adulthood.

Treuer, T., K. L. P. Chan, B. N. Kim, G. Kunjithapatham, D. Wynchank, B. Semerci, W. Montgomery, D. Novick, and H. Duenas. “Lost in Transition: A Review of the Unmet Need of Patients with Attention Deficit/Hyperactivity Disorder Transitioning to Adulthood.” [In eng]. Asia Pac Psychiatry 9, no. 2 (Jun 2017).

Effect of baicalin on behavioral characteristics of rats with attention deficit hyperactivity disorder .

Zhou, R. Y., X. M. Han, J. J. Wang, H. X. Yuan, J. C. Sun, Y. You, and Y. C. Song. “[Effect of Baicalin on Behavioral Characteristics of Rats with Attention Deficit Hyperactivity Disorder].” [In chi]. Zhongguo Dang Dai Er Ke Za Zhi 19, no. 8 (Aug 2017): 930-37.

Noninvasive cerebral stimulation for treatment of ADHD: A review of the literature .

Brandejsky, L., J. A. Micoulaud Franchi, R. Lopez, S. Bioulac, D. Da Fonseca, C. Daudet, L. Boyer, R. Richieri, and C. Lancon. “[Noninvasive Cerebral Stimulation for Treatment of Adhd: A Review of the Literature].” [In fre]. Encephale 43, no. 5 (Oct 2017): 457-63.

Diet and ADHD, Reviewing the Evidence: A Systematic Review of Meta-Analyses of Double-Blind Placebo-Controlled Trials Evaluating the Efficacy of Diet Interventions on the Behavior of Children with ADHD.

Pelsser, L. M., K. Frankena, J. Toorman, and R. Rodrigues Pereira. “Diet and Adhd, Reviewing the Evidence: A Systematic Review of Meta-Analyses of Double-Blind Placebo-Controlled Trials Evaluating the Efficacy of Diet Interventions on the Behavior of Children with Adhd.” [In eng]. PLoS One 12, no. 1 (2017): e0169277.

Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: Meta-analysis based on head-to-head trials.

Liu, Q., H. Zhang, Q. Fang, and L. Qin. “Comparative Efficacy and Safety of Methylphenidate and Atomoxetine for Attention-Deficit Hyperactivity Disorder in Children and Adolescents: Meta-Analysis Based on Head-to-Head Trials.” [In eng]. J Clin Exp Neuropsychol 39, no. 9 (Nov 2017): 854-65.

Cognitively and physically demanding exergaming to improve executive functions of children with attention deficit hyperactivity disorder: a randomised clinical trial.

Benzing, V., and M. Schmidt. “Cognitively and Physically Demanding Exergaming to Improve Executive Functions of Children with Attention Deficit Hyperactivity Disorder: A Randomised Clinical Trial.” [In eng]. BMC Pediatr 17, no. 1 (Jan 10 2017): 8.

Personalized features for attention detection in children with Attention Deficit Hyperactivity Disorder.

Fahimi, F., C. Guan, Goh Wooi Boon, Ang Kai Keng, Lim Choon Guan, and Lee Tih Shih. “Personalized Features for Attention Detection in Children with Attention Deficit Hyperactivity Disorder.” [In eng]. Conf Proc IEEE Eng Med Biol Soc 2017 (Jul 2017): 414-17.

EMG biofeedback training in adult attention-deficit/hyperactivity disorder: An active (control) training?

Barth, B., K. Mayer, U. Strehl, A. J. Fallgatter, and A. C. Ehlis. “Emg Biofeedback Training in Adult Attention-Deficit/Hyperactivity Disorder: An Active (Control) Training?” [In eng]. Behav Brain Res 329 (Jun 30 2017): 58-66.

Inter- and Intraindividual Variation of Methylphenidate Concentrations in Serum and Saliva of Patients with Attention-Deficit/Hyperactivity Disorder.

Preiskorn, J., S. Studer, R. Rauh, R. Lukacin, C. Geffert, C. Fleischhaker, H. W. Clement, E. Schulz, and M. Biscaldi. “Interindividual and Intraindividual Variation of Methylphenidate Concentrations in Serum and Saliva of Patients with Attention-Deficit/Hyperactivity Disorder.” [In eng]. Ther Drug Monit 40, no. 4 (Aug 2018): 435-42.

The age-dependent effects of a single-dose methylphenidate challenge on cerebral perfusion in patients with attention-deficit/hyperactivity disorder.

Schrantee, A., H. Mutsaerts, C. Bouziane, H. Tamminga, M. A. Bottelier, and L. Reneman. “The Age-Dependent Effects of a Single-Dose Methylphenidate Challenge on Cerebral Perfusion in Patients with Attention-Deficit/Hyperactivity Disorder.” [In eng]. Neuroimage Clin 13 (2017): 123-29.

An update on the safety of psychostimulants for the treatment of attention-deficit/hyperactivity disorder.

Groenman, A. P., L. J. Schweren, A. Dietrich, and P. J. Hoekstra. “An Update on the Safety of Psychostimulants for the Treatment of Attention-Deficit/Hyperactivity Disorder.” [In eng]. Expert Opin Drug Saf 16, no. 4 (Apr 2017): 455-64.

Chronic Methylphenidate Alters Tonic and Phasic Glutamate Signaling in the Frontal Cortex of a Freely-Moving Rat Model of ADHD.

Miller, E. M., J. E. Quintero, F. Pomerleau, P. Huettl, G. A. Gerhardt, and P. E. A. Glaser. “Chronic Methylphenidate Alters Tonic and Phasic Glutamate Signaling in the Frontal Cortex of a Freely-Moving Rat Model of Adhd.” [In eng]. Neurochem Res (Feb 3 2018).

A Randomized Controlled Trial to Examine the Posttreatment Efficacy of Neurofeedback, Behavior Therapy, and Pharmacology on ADHD Measures.

Moreno-Garcia, I., S. Meneres-Sancho, C. Camacho-Vara de Rey, and M. Servera. “A Randomized Controlled Trial to Examine the Posttreatment Efficacy of Neurofeedback, Behavior Therapy, and Pharmacology on Adhd Measures.” [In eng]. J Atten Disord (Feb 1 2017): 1087054717693371.

The safety of extended-release drug formulations for the treatment of ADHD.

Childress, A. “The Safety of Extended-Release Drug Formulations for the Treatment of Adhd.” [In eng]. Expert Opin Drug Saf 16, no. 5 (May 2017): 603-15.

A double-blind placebo-controlled randomised trial of omega-3 supplementation in children with moderate ADHD symptoms.

Cornu, C., C. Mercier, T. Ginhoux, S. Masson, J. Mouchet, P. Nony, B. Kassai, et al. “A Double-Blind Placebo-Controlled Randomised Trial of Omega-3 Supplementation in Children with Moderate Adhd Symptoms.” [In eng]. Eur Child Adolesc Psychiatry 27, no. 3 (Mar 2018): 377-84.

Histamine H3 receptor antagonists ameliorate attention deficit/hyperactivity disorder-like behavioral changes caused by neonatal habenula lesion.

Kim, Y. J., Y. Goto, and Y. A. Lee. “Histamine H3 Receptor Antagonists Ameliorate Attention Deficit/Hyperactivity Disorder-Like Behavioral Changes Caused by Neonatal Habenula Lesion.” [In eng]. Behav Pharmacol 29, no. 1 (Feb 2018): 71-78.

Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of adverse events in non-randomised studies.

Storebo, O. J., N. Pedersen, E. Ramstad, M. L. Kielsholm, S. S. Nielsen, H. B. Krogh, C. R. Moreira-Maia, et al. “Methylphenidate for Attention Deficit Hyperactivity Disorder (Adhd) in Children and Adolescents – Assessment of Adverse Events in Non-Randomised Studies.” [In eng]. Cochrane Database Syst Rev 5 (May 9 2018): CD012069.

Additive effects of neurofeedback on the treatment of ADHD: A randomized controlled study.

Lee, E. J., and C. H. Jung. “Additive Effects of Neurofeedback on the Treatment of Adhd: A Randomized Controlled Study.” [In eng]. Asian J Psychiatr 25 (Feb 2017): 16-21.

ADHD in Germany: Trends in Diagnosis and Pharmacotherapy.

Bachmann, C. J., A. Philipsen, and F. Hoffmann. “Adhd in Germany: Trends in Diagnosis and Pharmacotherapy.” [In eng]. Dtsch Arztebl Int 114, no. 9 (Mar 3 2017): 141-48.

Autism Spectrum disorder classification, diagnosis and therapy.

Sharma, S. R., X. Gonda, and F. I. Tarazi. “Autism Spectrum Disorder: Classification, Diagnosis and Therapy.” [In eng]. Pharmacol Ther (May 12 2018).

Weeding Out the Justification for Marijuana Treatment in Patients with Developmental and Behavioral Conditions.

Nelson, T., Y. H. Liu, K. S. Bagot, and M. T. Stein. “Weeding out the Justification for Marijuana Treatment in Patients with Developmental and Behavioral Conditions.” [In eng]. J Dev Behav Pediatr 38, no. 6 (Jul/Aug 2017): 446-48.

Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.

Pliszka, S. R., T. E. Wilens, S. Bostrom, V. K. Arnold, A. Marraffino, A. J. Cutler, F. A. Lopez, et al. “Efficacy and Safety of Hld200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.” [In eng]. J Child Adolesc Psychopharmacol 27, no. 6 (Aug 2017): 474-82.

Neurofeedback: One of today’s techniques in psychiatry?

Arns, M., J. M. Batail, S. Bioulac, M. Congedo, C. Daudet, D. Drapier, T. Fovet, et al. “Neurofeedback: One of Today’s Techniques in Psychiatry?” [In eng]. Encephale 43, no. 2 (Apr 2017): 135-45.

Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis.

Cortese, S., N. Adamo, C. Mohr-Jensen, A. J. Hayes, S. Bhatti, S. Carucci, C. Del Giovane, et al. “Comparative Efficacy and Tolerability of Pharmacological Interventions for Attention-Deficit/Hyperactivity Disorder in Children, Adolescents and Adults: Protocol for a Systematic Review and Network Meta-Analysis.” [In eng]. BMJ Open 7, no. 1 (Jan 10 2017): e013967.

Herbal medicines in children with attention deficit hyperactivity disorder (ADHD): a systematic review.

Anheyer, D., R. Lauche, D. Schumann, G. Dobos, and H. Cramer. “Herbal Medicines in Children with Attention Deficit Hyperactivity Disorder (Adhd): A Systematic Review.” [In eng]. Complement Ther Med 30 (Feb 2017): 14-23.

Attention-deficit/hyperactivity disorder medication and seizures.

Wiggs, K. K., Z. Chang, P. D. Quinn, K. Hur, R. Gibbons, D. Dunn, I. Brikell, H. Larsson, and B. M. D’Onofrio. “Attention-Deficit/Hyperactivity Disorder Medication and Seizures.” [In eng]. Neurology 90, no. 13 (Mar 27 2018): e1104-e10.

Aripiprazole Selectively Reduces Motor Tics in a Young Animal Model for Tourette’s Syndrome and Comorbid Attention Deficit and Hyperactivity Disorder.

Rizzo, F., E. Nespoli, A. Abaei, I. Bar-Gad, D. K. Deelchand, J. Fegert, V. Rasche, B. Hengerer, and T. M. Boeckers. “Aripiprazole Selectively Reduces Motor Tics in a Young Animal Model for Tourette’s Syndrome and Comorbid Attention Deficit and Hyperactivity Disorder.” [In eng]. Front Neurol 9 (2018): 59.

Evaluating the pragmatic language skills of children with ADHD and typically developing playmates following a pilot parent-delivered play-based intervention.

Cordier, R., N. Munro, S. Wilkes-Gillan, L. Ling, K. Docking, and W. Pearce. “Evaluating the Pragmatic Language Skills of Children with Adhd and Typically Developing Playmates Following a Pilot Parent-Delivered Play-Based Intervention.” [In eng]. Aust Occup Ther J 64, no. 1 (Feb 2017): 11-23.

Adverse Gestational Outcomes Associated With Attention-Deficit/Hyperactivity Disorder Medication Exposure During Pregnancy.

Andrade, C. “Adverse Gestational Outcomes Associated with Attention-Deficit/Hyperactivity Disorder Medication Exposure During Pregnancy.” [In eng]. J Clin Psychiatry 79, no. 1 (Jan/Feb 2018).

Efficacy and Tolerability of Different Interventions in Children and Adolescents with Attention Deficit Hyperactivity Disorder.

Luan, R., Z. Mu, F. Yue, and S. He. “Efficacy and Tolerability of Different Interventions in Children and Adolescents with Attention Deficit Hyperactivity Disorder.” [In eng]. Front Psychiatry 8 (2017): 229.

Aripiprazole and Riluzole treatment alters behavior and neurometabolites in young ADHD rats: a longitudinal

Rizzo, F., A. Abaei, E. Nespoli, J. M. Fegert, B. Hengerer, V. Rasche, and T. M. Boeckers. “Aripiprazole and Riluzole Treatment Alters Behavior and Neurometabolites in Young Adhd Rats: A Longitudinal (1)H-Nmr Spectroscopy Study at 11.7t.” [In eng]. Transl Psychiatry 7, no. 8 (Aug 1 2017): e1189.

Childhood epilepsy and ADHD comorbidity in an Indian tertiary medical center outpatient population.

Choudhary, A., S. Gulati, R. Sagar, N. Sankhyan, and K. Sripada. “Childhood Epilepsy and Adhd Comorbidity in an Indian Tertiary Medical Center Outpatient Population.” [In eng]. Sci Rep 8, no. 1 (Feb 8 2018): 2670.

Informant-related effects of neurofeedback and cognitive training in children with ADHD including a waiting control phase: a randomized-controlled trial.

Minder, F., A. Zuberer, D. Brandeis, and R. Drechsler. “Informant-Related Effects of Neurofeedback and Cognitive Training in Children with Adhd Including a Waiting Control Phase: A Randomized-Controlled Trial.” [In eng]. Eur Child Adolesc Psychiatry 27, no. 8 (Aug 2018): 1055-66.

Elimination diets’ efficacy and mechanisms in attention deficit hyperactivity disorder and autism spectrum disorder.

Ly, V., M. Bottelier, P. J. Hoekstra, A. Arias Vasquez, J. K. Buitelaar, and N. N. Rommelse. “Elimination Diets’ Efficacy and Mechanisms in Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder.” [In eng]. Eur Child Adolesc Psychiatry 26, no. 9 (Sep 2017): 1067-79.

Disrupted Glutamatergic Transmission in Prefrontal Cortex Contributes to Behavioral Abnormality in an Animal Model of ADHD.

Cheng, J., A. Liu, M. Y. Shi, and Z. Yan. “Disrupted Glutamatergic Transmission in Prefrontal Cortex Contributes to Behavioral Abnormality in an Animal Model of Adhd.” [In eng]. Neuropsychopharmacology 42, no. 10 (Sep 2017): 2096-104.

Near-Infrared Spectroscopy-Based Frontal Lobe Neurofeedback Integrated in Virtual Reality Modulates Brain and Behavior in Highly Impulsive Adults.

Hudak, J., F. Blume, T. Dresler, F. B. Haeussinger, T. J. Renner, A. J. Fallgatter, C. Gawrilow, and A. C. Ehlis. “Near-Infrared Spectroscopy-Based Frontal Lobe Neurofeedback Integrated in Virtual Reality Modulates Brain and Behavior in Highly Impulsive Adults.” [In eng]. Front Hum Neurosci 11 (2017): 425.

ESCAlate – Adaptive treatment approach for adolescents and adults with ADHD: study protocol for a randomized controlled trial.

Zinnow, T., T. Banaschewski, A. J. Fallgatter, C. Jenkner, F. Philipp-Wiegmann, A. Philipsen, W. Retz, et al. “Escalate – Adaptive Treatment Approach for Adolescents and Adults with Adhd: Study Protocol for a Randomized Controlled Trial.” [In eng]. Trials 19, no. 1 (May 18 2018): 280.

Risk of unintentional injuries in children and adolescents with ADHD and the impact of ADHD medications: protocol for a systematic review and meta-analysis.

Ruiz-Goikoetxea, M., S. Cortese, M. Aznarez-Sanado, S. Magallon, E. O. Luis, N. Alvarez Zallo, P. Castro-Manglano, C. Soutullo, and G. Arrondo. “Risk of Unintentional Injuries in Children and Adolescents with Adhd and the Impact of Adhd Medications: Protocol for a Systematic Review and Meta-Analysis.” [In eng]. BMJ Open 7, no. 9 (Sep 25 2017): e018027.

Perinatal Outcomes After Treatment With ADHD Medication During Pregnancy.

Norby, U., B. Winbladh, and K. Kallen. “Perinatal Outcomes after Treatment with Adhd Medication During Pregnancy.” [In eng]. Pediatrics 140, no. 6 (Dec 2017).

Neurofeedback in Parkinson’s disease: technologies in speech and language therapy.

Lavermicocca, V., A. R. Dellomonaco, A. Tedesco, M. Notarnicola, R. Di Fede, and P. P. Battaglini. “[Neurofeedback in Parkinson’s Disease: Technologies in Speech and Language Therapy.].” [In ita]. Recenti Prog Med 109, no. 2 (Feb 2018): 130-32.

Cross-species studies of cognition relevant to drug discovery: a translational approach.

Robbins, T. W. “Cross-Species Studies of Cognition Relevant to Drug Discovery: A Translational Approach.” [In eng]. Br J Pharmacol 174, no. 19 (Oct 2017): 3191-99.

Beneficial Effects of Everolimus on Autism and Attention-Deficit/Hyperactivity Disorder Symptoms in a Group of Patients with Tuberous Sclerosis Complex.

Kilincaslan, A., B. E. Kok, P. Tekturk, C. Yalcinkaya, C. Ozkara, and Z. Yapici. “Beneficial Effects of Everolimus on Autism and Attention-Deficit/Hyperactivity Disorder Symptoms in a Group of Patients with Tuberous Sclerosis Complex.” [In eng]. J Child Adolesc Psychopharmacol 27, no. 4 (May 2017): 383-88.

Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting.

Childress, A. C., S. H. Kollins, A. J. Cutler, A. Marraffino, and C. R. Sikes. “Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting.” [In eng]. J Child Adolesc Psychopharmacol 27, no. 1 (Feb 2017): 66-74.

An Evaluation Approach for the Performance of Dosing Regimens in Attention-Deficit/Hyperactivity Disorder Treatment.

Bonnefois, G., P. Robaey, O. Barriere, J. Li, and F. Nekka. “An Evaluation Approach for the Performance of Dosing Regimens in Attention-Deficit/Hyperactivity Disorder Treatment.” [In eng]. J Child Adolesc Psychopharmacol 27, no. 4 (May 2017): 320-31.

Pharmacokinetics and Pharmacodynamics of Lisdexamfetamine Compared with D-Amphetamine in Healthy Subjects.

Dolder, P. C., P. Strajhar, P. Vizeli, F. Hammann, A. Odermatt, and M. E. Liechti. “Pharmacokinetics and Pharmacodynamics of Lisdexamfetamine Compared with D-Amphetamine in Healthy Subjects.” [In eng]. Front Pharmacol 8 (2017): 617.

Methylphenidate Induced Lip and Tongue Biting.

Gokcen, C., M. Karadag, and I. Aksoy. “Methylphenidate Induced Lip and Tongue Biting.” [In eng]. Clin Psychopharmacol Neurosci 16, no. 2 (May 31 2018): 218-20.

Case report: Cytochrome P450 implications for comorbid ADHD and OCD pharmacotherapy.

Hogan, M. K., and N. P. Rao. “Case Report: Cytochrome P450 Implications for Comorbid Adhd and Ocd Pharmacotherapy.” [In eng]. J Child Adolesc Psychiatr Nurs 30, no. 3 (Aug 2017): 126-32.

Misuse of Methylphenidate.

Clemow, D. B. “Misuse of Methylphenidate.” [In eng]. Curr Top Behav Neurosci 34 (2017): 99-124.

The Mixed Opioid Receptor Antagonist Naltrexone Mitigates Stimulant-Induced Euphoria: A Double-Blind, Placebo-Controlled Trial of Naltrexone.

Spencer, T. J., P. Bhide, J. Zhu, S. V. Faraone, M. Fitzgerald, A. M. Yule, M. Uchida, et al. “The Mixed Opioid Receptor Antagonist Naltrexone Mitigates Stimulant-Induced Euphoria: A Double-Blind, Placebo-Controlled Trial of Naltrexone.” [In eng]. J Clin Psychiatry 79, no. 2 (Mar/Apr 2018).

The 5 Choice Continuous Performance Test (5C-CPT): A novel tool to assess cognitive control across species.

Bhakta, S. G., and J. W. Young. “The 5 Choice Continuous Performance Test (5c-Cpt): A Novel Tool to Assess Cognitive Control across Species.” [In eng]. J Neurosci Methods 292 (Dec 1 2017): 53-60.

The effect of metilpheniydate, risperidone and combination therapy on ECG in children with attention-deficit hyperactivity disorder.

Karpuz, D., O. Hallioglu, F. Toros, and B. Tasdelen. “The Effect of Metilpheniydate, Risperidone and Combination Therapy on Ecg in Children with Attention-Deficit Hyperactivity Disorder.” [In eng]. J Electrocardiol 50, no. 4 (Jul – Aug 2017): 410-15.

Discontinuation of pharmacological treatment of children and adolescents with attention deficit hyperactivity disorder: meta-analysis of 63 studies enrolling 11,788 patients.

Riera, M., X. Castells, A. Tobias, R. Cunill, L. Blanco, and D. Capella. “Discontinuation of Pharmacological Treatment of Children and Adolescents with Attention Deficit Hyperactivity Disorder: Meta-Analysis of 63 Studies Enrolling 11,788 Patients.” [In eng]. Psychopharmacology (Berl) 234, no. 17 (Sep 2017): 2657-71.

The acute social defeat stress and nest-building test paradigm: A potential new method to screen drugs for depressive-like symptoms.

Otabi, H., T. Goto, T. Okayama, D. Kohari, and A. Toyoda. “The Acute Social Defeat Stress and Nest-Building Test Paradigm: A Potential New Method to Screen Drugs for Depressive-Like Symptoms.” [In eng]. Behav Processes 135 (Feb 2017): 71-75.

Imitations and Transformations: On Side Effects of the ADHD Epidemic.

Nielsen, B. “Imitations and Transformations: On Side Effects of the Adhd Epidemic.” [In eng]. Med Anthropol 36, no. 3 (Apr 2017): 246-59.

Prescribing Trends of Atypical Antipsychotic Drugs in an Outpatient Unit of a Child and Adolescent Clinic in Turkey.

Yektas, C., and A. E. Tufan. “Prescribing Trends of Atypical Antipsychotic Drugs in an Outpatient Unit of a Child and Adolescent Clinic in Turkey.” [In eng]. Clin Neuropharmacol 41, no. 1 (Jan/Feb 2018): 23-27.

Brain-Computer Interface for Clinical Purposes: Cognitive Assessment and Rehabilitation.

Carelli, L., F. Solca, A. Faini, P. Meriggi, D. Sangalli, P. Cipresso, G. Riva, et al. “Brain-Computer Interface for Clinical Purposes: Cognitive Assessment and Rehabilitation.” [In eng]. Biomed Res Int 2017 (2017): 1695290.

An update on pharmacotherapy of autism spectrum disorder in children and adolescents.

Goel, R., J. S. Hong, R. L. Findling, and N. Y. Ji. “An Update on Pharmacotherapy of Autism Spectrum Disorder in Children and Adolescents.” [In eng]. Int Rev Psychiatry 30, no. 1 (Feb 2018): 78-95.

Hemodynamic profile and behavioral characteristics during induction of anesthesia in pediatric patients with attention deficit hyperactivity disorder.

Cartabuke, R. S., J. D. Tobias, J. Rice, and D. Tumin. “Hemodynamic Profile and Behavioral Characteristics During Induction of Anesthesia in Pediatric Patients with Attention Deficit Hyperactivity Disorder.” [In eng]. Paediatr Anaesth 27, no. 4 (Apr 2017): 417-24.

Olanzapine-induced Priapism in a Child with Asperger’s Syndrome.

Bozkurt, H., and S. Sahin. “Olanzapine-Induced Priapism in a Child with Asperger’s Syndrome.” [In eng]. Balkan Med J 34, no. 1 (Jan 2017): 85-87.

Fasoracetam in adolescents with ADHD and glutamatergic gene network variants disrupting mGluR neurotransmitter signaling.

Elia, J., G. Ungal, C. Kao, A. Ambrosini, N. De Jesus-Rosario, L. Larsen, R. Chiavacci, et al. “Fasoracetam in Adolescents with Adhd and Glutamatergic Gene Network Variants Disrupting Mglur Neurotransmitter Signaling.” [In eng]. Nat Commun 9, no. 1 (Jan 16 2018): 4.

ADHD and Anxiety: Clinical Significance and Treatment Implications.

Reimherr, F. W., B. K. Marchant, T. E. Gift, and T. A. Steans. “Adhd and Anxiety: Clinical Significance and Treatment Implications.” [In eng]. Curr Psychiatry Rep 19, no. 12 (Nov 20 2017): 109.

Methylphenidate effects in the young brain: friend or foe?

Loureiro-Vieira, S., V. M. Costa, M. de Lourdes Bastos, F. Carvalho, and J. P. Capela. “Methylphenidate Effects in the Young Brain: Friend or Foe?” [In eng]. Int J Dev Neurosci 60 (Aug 2017): 34-47.

Model-Based Approach for Optimizing Study Design and Clinical Drug Performances of Extended-Release Formulations of Methylphenidate for the Treatment of ADHD.

Gomeni, R., F. Bressolle-Gomeni, T. J. Spencer, S. V. Faraone, L. Fang, and A. Babiskin. “Model-Based Approach for Optimizing Study Design and Clinical Drug Performances of Extended-Release Formulations of Methylphenidate for the Treatment of Adhd.” [In eng]. Clin Pharmacol Ther 102, no. 6 (Dec 2017): 951-60.

Methylphenidate clinically oral doses improved brain and heart glutathione redox status and evoked renal and cardiac tissue injury in rats.

Loureiro-Vieira, S., V. M. Costa, J. A. Duarte, M. Duarte-Araujo, S. Goncalves-Monteiro, B. Maria de Lourdes, F. Carvalho, and J. P. Capela. “Methylphenidate Clinically Oral Doses Improved Brain and Heart Glutathione Redox Status and Evoked Renal and Cardiac Tissue Injury in Rats.” [In eng]. Biomed Pharmacother 100 (Apr 2018): 551-63.

Practitioner Review: Treatment of chronic insomnia in children and adolescents with neurodevelopmental disabilities.

Bruni, O., M. Angriman, F. Calisti, A. Comandini, G. Esposito, S. Cortese, and R. Ferri. “Practitioner Review: Treatment of Chronic Insomnia in Children and Adolescents with Neurodevelopmental Disabilities.” [In eng]. J Child Psychol Psychiatry 59, no. 5 (May 2018): 489-508.

Vitamin-Mineral Treatment of ADHD in Adults.

Rucklidge, J. J., C. M. Frampton, B. Gorman, and A. Boggis. “Vitamin-Mineral Treatment of Adhd in Adults.” [In eng]. J Atten Disord 21, no. 6 (Apr 2017): 522-32.

Pharmacokinetics of a New Amphetamine Extended-release Oral Liquid Suspension Under Fasted and Fed Conditions in Healthy Adults: A Randomized, Open-label, Single-dose, 3-treatment Study.

Sikes, C., J. G. Stark, R. McMahen, and D. Engelking. “Pharmacokinetics of a New Amphetamine Extended-Release Oral Liquid Suspension under Fasted and Fed Conditions in Healthy Adults: A Randomized, Open-Label, Single-Dose, 3-Treatment Study.” [In eng]. Clin Ther 39, no. 12 (Dec 2017): 2389-98.

NeuroAIDS in children.

Wilmshurst, J. M., C. K. Hammond, K. Donald, J. Hoare, K. Cohen, and B. Eley. “Neuroaids in Children.” [In eng]. Handb Clin Neurol 152 (2018): 99-116.

Effect of Food Intake on the Pharmacokinetics of a Novel Methylphenidate Extended-Release Oral Suspension for Attention Deficit Hyperactivity Disorder.

Sallee, F. R., D. R. Palumbo, R. Abbas, S. A. Berry, S. P. Puthli, and K. K. Kathala. “Effect of Food Intake on the Pharmacokinetics of a Novel Methylphenidate Extended-Release Oral Suspension for Attention Deficit Hyperactivity Disorder.” [In eng]. Clin Pharmacol Drug Dev 6, no. 5 (Sep 2017): 476-83.

Toxicity assessment of molindone hydrochloride, a dopamine D2/D5 receptor antagonist in juvenile and adult rats.

Krishna, G., G. Gopalakrishnan, and S. Goel. “Toxicity Assessment of Molindone Hydrochloride, a Dopamine D2/D5 Receptor Antagonist in Juvenile and Adult Rats.” [In eng]. Toxicol Mech Methods 27, no. 5 (Jun 2017): 352-62.

Treatment issues for children with epilepsy transitioning to adult care.

Nabbout, R., C. S. Camfield, D. M. Andrade, A. Arzimanoglou, C. Chiron, J. A. Cramer, J. A. French, et al. “Treatment Issues for Children with Epilepsy Transitioning to Adult Care.” [In eng]. Epilepsy Behav 69 (Apr 2017): 153-60.

Methylphenidate enhances neuronal differentiation and reduces proliferation concomitant to activation of Wnt signal transduction pathways.

Grunblatt, E., J. Bartl, and S. Walitza. “Methylphenidate Enhances Neuronal Differentiation and Reduces Proliferation Concomitant to Activation of Wnt Signal Transduction Pathways.” [In eng]. Transl Psychiatry 8, no. 1 (Mar 1 2018): 51.

Physician practices to prevent ADHD stimulant diversion and misuse.

Colaneri, N., S. Keim, and A. Adesman. “Physician Practices to Prevent Adhd Stimulant Diversion and Misuse.” [In eng]. J Subst Abuse Treat 74 (Mar 2017): 26-34.

Association of Fluid Intelligence and Psychiatric Disorders in a Population-Representative Sample of US Adolescents.

Keyes, K. M., J. Platt, A. S. Kaufman, and K. A. McLaughlin. “Association of Fluid Intelligence and Psychiatric Disorders in a Population-Representative Sample of Us Adolescents.” [In eng]. JAMA Psychiatry 74, no. 2 (Feb 1 2017): 179-88.

Comparison of the VTA and LC response to methylphenidate: a concomitant behavioral and neuronal study of adolescent male rats.

Karim, T. J., C. Reyes-Vazquez, and N. Dafny. “Comparison of the Vta and Lc Response to Methylphenidate: A Concomitant Behavioral and Neuronal Study of Adolescent Male Rats.” [In eng]. J Neurophysiol 118, no. 3 (Sep 1 2017): 1501-14.

Palmitoylation mechanisms in dopamine transporter regulation.

Rastedt, D. E., R. A. Vaughan, and J. D. Foster. “Palmitoylation Mechanisms in Dopamine Transporter Regulation.” [In eng]. J Chem Neuroanat 83-84 (Oct 2017): 3-9.

Impaired oral absorption of methylphenidate after Roux-en-Y gastric bypass.

Azran, C., P. Langguth, and A. Dahan. “Impaired Oral Absorption of Methylphenidate after Roux-En-Y Gastric Bypass.” [In eng]. Surg Obes Relat Dis 13, no. 7 (Jul 2017): 1245-47.

Adherence to antiepileptic drugs in children and adolescents: A retrospective study in primary care settings in Germany.

Jacob, L., H. M. Hamer, and K. Kostev. “Adherence to Antiepileptic Drugs in Children and Adolescents: A Retrospective Study in Primary Care Settings in Germany.” [In eng]. Epilepsy Behav 75 (Oct 2017): 36-41.

Change in BMI after radioactive iodine ablation for Graves disease.

Chen, M., M. Lash, T. Nebesio, and E. Eugster. “Change in Bmi after Radioactive Iodine Ablation for Graves Disease.” [In eng]. Int J Pediatr Endocrinol 2017 (2017): 5.

Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Guanfacine Extended-Release Formulation in Healthy Japanese and Caucasian Male Adults.

Matsuo, Y., M. Okita, J. Ermer, and T. Wajima. “Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Guanfacine Extended-Release Formulation in Healthy Japanese and Caucasian Male Adults.” [In eng]. Clin Drug Investig 37, no. 8 (Aug 2017): 745-53.

Oral healthcare for the persons with special needs.

Morisaki, I. “[Oral Healthcare for the Persons with Special Needs.].” [In jpn]. Clin Calcium 27, no. 10 (2017): 1417-25.

Lisdexamfetamine: A Review in Binge Eating Disorder.

Heo, Y. A., and S. T. Duggan. “Lisdexamfetamine: A Review in Binge Eating Disorder.” [In eng]. CNS Drugs 31, no. 11 (Nov 2017): 1015-22.

Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis.

Veroniki, A. A., P. Rios, E. Cogo, S. E. Straus, Y. Finkelstein, R. Kealey, E. Reynen, et al. “Comparative Safety of Antiepileptic Drugs for Neurological Development in Children Exposed During Pregnancy and Breast Feeding: A Systematic Review and Network Meta-Analysis.” [In eng]. BMJ Open 7, no. 7 (Jul 20 2017): e017248.

Mazindol: a risk factor for pulmonary arterial hypertension?

Konofal, E., C. Benzouid, C. Delclaux, M. Lecendreux, and E. Hussey. “Mazindol: A Risk Factor for Pulmonary Arterial Hypertension?” [In eng]. Sleep Med 34 (Jun 2017): 168-69.

Transient Isolated Lower Bulbar Palsy With Elevated Serum Anti-GM1 and Anti-GD1b Antibodies During Aripiprazole Treatment.

Han, T. H., D. Y. Kim, D. W. Park, and J. H. Moon. “Transient Isolated Lower Bulbar Palsy with Elevated Serum Anti-Gm1 and Anti-Gd1b Antibodies During Aripiprazole Treatment.” [In eng]. Pediatr Neurol 66 (Jan 2017): 96-99.

Toxicity of the amphetamine metabolites 4-hydroxyamphetamine and 4-hydroxynorephedrine in human dopaminergic differentiated SH-SY5Y cells.

Feio-Azevedo, R., V. M. Costa, L. M. Ferreira, P. S. Branco, F. C. Pereira, M. L. Bastos, F. Carvalho, and J. P. Capela. “Toxicity of the Amphetamine Metabolites 4-Hydroxyamphetamine and 4-Hydroxynorephedrine in Human Dopaminergic Differentiated Sh-Sy5y Cells.” [In eng]. Toxicol Lett 269 (Mar 5 2017): 65-76.

The Effect of Myricetin on Pharmacokinetics of Atomoxetine and its Metabolite 4-Hydroxyatomoxetine In Vivo and In Vitro.

Lan, T., X. X. Hu, B. Q. Liang, W. H. Pan, Q. Zhou, L. J. Yuan, and G. X. Hu. “The Effect of Myricetin on Pharmacokinetics of Atomoxetine and Its Metabolite 4-Hydroxyatomoxetine in Vivo and in Vitro.” [In eng]. Eur J Drug Metab Pharmacokinet 42, no. 2 (Apr 2017): 261-68.

Nutritional Psychiatry: Where to Next?

Jacka, F. N. “Nutritional Psychiatry: Where to Next?” [In eng]. EBioMedicine 17 (Mar 2017): 24-29.

The efficacy and safety of extended-release methylphenidate following traumatic brain injury: a randomised controlled pilot study.

Dymowski, A. R., J. L. Ponsford, J. A. Owens, J. H. Olver, M. Ponsford, and C. Willmott. “The Efficacy and Safety of Extended-Release Methylphenidate Following Traumatic Brain Injury: A Randomised Controlled Pilot Study.” [In eng]. Clin Rehabil 31, no. 6 (Jun 2017): 733-41.

Brief psychosis induced by methylphenidate in a child with attention deficit disorder: a case report and literature review.

Martinez-Aguayo, J. C., M. Arancibia, N. Meza-Concha, C. Bustamante, J. Perez-Bracchiglione, and E. Madrid. “Brief Psychosis Induced by Methylphenidate in a Child with Attention Deficit Disorder: A Case Report and Literature Review.” [In spa eng]. Medwave 17, no. 5 (Jun 21 2017): e6980.

Persistent neuropsychiatric impairment in HCV patients despite clearance of the virus?!

Dirks, M., H. Pflugrad, K. Haag, H. L. Tillmann, H. Wedemeyer, D. Arvanitis, H. Hecker, et al. “Persistent Neuropsychiatric Impairment in Hcv Patients Despite Clearance of the Virus?!” [In eng]. J Viral Hepat 24, no. 7 (Jul 2017): 541-50.

Atypical antipsychotics for disruptive behaviour disorders in children and youths.

Loy, J. H., S. N. Merry, S. E. Hetrick, and K. Stasiak. “Atypical Antipsychotics for Disruptive Behaviour Disorders in Children and Youths.” [In eng]. Cochrane Database Syst Rev 8 (Aug 9 2017): CD008559.

Reduced functional connectivity of fronto-parietal sustained attention networks in severe childhood abuse.

Hart, H., L. Lim, M. A. Mehta, A. Chatzieffraimidou, C. Curtis, X. Xu, G. Breen, et al. “Reduced Functional Connectivity of Fronto-Parietal Sustained Attention Networks in Severe Childhood Abuse.” [In eng]. PLoS One 12, no. 11 (2017): e0188744.